| Name | Title | Contact Details |
|---|
Marathon Health is based in Indianapolis, IN and Winooski, VT. When we say we are a different kind of healthcare company, we mean we`re a better kind. What makes us better is that we guide people to take control of their own health. We operate on a simple premise: when people are given the tools they need to manage their own health and healthcare, the cost of healthcare is lower. We believe the best way to keep people healthy is to help them manage risk factors and chronic conditions, and to keep them from getting sick in the first place. To do this, we combine a powerful collection of onsite health services into a program tailored to your unique culture, setting, and workforce.
Apria Lifeplus is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Veran Medical Technologies, Inc., an image guided medical device company, develops a suite of products to enable physicians to diagnose disease and deliver therapies. It offers standards for minimally invasive delivery of interventional oncology therapies. The company provides plug-n-play delivery systems and navigated instruments. Its IG4 Platform allows clinicians to visualize various types of information integrated with a CT dataset, such as respiration, contrast enhanced structures, PET, and ultrasound. The company also provides SPiN Drive System that acts as a GPS-like system to enable pulmonologists and surgeons to access peripheral solitary pulmonary nodules to diagnose malignancy. Veran Medical Technologies, Inc. was incorporated in 2007 and is headquartered in St. Louis, Missouri.
Stemgent Inc is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.